The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Open accessAbstract
BACKGROUND: Lung cancer is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung cancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information. METHODS: Using data from Surveillance, Epidemiology, and End Results (SEER) areas, we assessed lung-cancer mortality and linked deaths from lung cancer to incident cases in SEER cancer registries. This allowed us to evaluate population-level mortality trends attributed to specific subtypes (incidence-based mortality). We also evaluated lung-cancer incidence and survival according to cancer subtype, sex, and calendar year. Joinpoint software was used to assess changes in incidence and trends in incidence-based mortality. RESULTS: Mortality from NSCLC decreased even faster than the incidence of this subtype, and this decrease was associated with a substantial improvement in survival over time that corresponded to the timing of approval of targeted therapy. Among men, incidence-based mortality from NSCLC decreased 6.3% annually from 2013 through 2016, whereas the incidence decreased 3.1% annually from 2008 through 2016. Corresponding lung cancer-specific survival improved from 26% among men with NSCLC that was diagnosed in 2001 to 35% among those in whom it was diagnosed in 2014. This improvement in survival was found across all races and ethnic groups. Similar patterns were found among women with NSCLC. In contrast, mortality from SCLC declined almost entirely as a result of declining incidence, with no improvement in survival. This result correlates with limited treatment advances for SCLC in the time frame we examined. CONCLUSIONS: Population-level mortality from NSCLC in the United States fell sharply from 2013 to 2016, and survival after diagnosis improved substantially. Our analysis suggests that a reduction in incidence along with treatment advances - particularly approvals for and use of targeted therapies - is likely to explain the reduction in mortality observed during this period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Permutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
Self-citationOsimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,905
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E., Paz-Ares, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3062 · Cited by 861
Ethnic and Racial Differences in the Smoking-Related Risk of Lung Cancer
Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E., & Le Marchand, L. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa033250 · Cited by 781
Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015
Jemal, A., & Fedewa, S. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6416 · Cited by 530
Trends in esophageal adenocarcinoma incidence and mortality
Hur, C., Miller, M., Kong, C. Y., Dowling, E. C., Nattinger, K. J., Dunn, M., & Feuer, E. J. (2013) · Cancer · doi:10.1002/cncr.27834 · Cited by 507
Self-citationResensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Shaw, A. T., Friboulet, L., Leshchiner, I., Gainor, J. F., Bergqvist, S., Brooun, A., Burke, B. J., Deng, Y.-L., Liu, W., Dardaei, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508887 · Cited by 484
Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010
Meza, R., Meernik, C., Jeon, J., & Cote, M. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121323 · Cited by 363
Self-citationWard, E. M., Sherman, R. L., Henley, S. J., Jemal, A., Siegel, D. A., Feuer, E. J., Firth, A. U., Kohler, B. A., Scott, S., Ma, J., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz106 · Cited by 323
Self-citationCancer Survival: An Overview of Measures, Uses, and Interpretation
Mariotto, A. B., Noone, A.-M., Howlader, N., Cho, H., Keel, G. E., Garshell, J., Woloshin, S., & Schwartz, L. M. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu024 · Cited by 295
Self-citationComparison of aspects of smoking among the four histological types of lung cancer
Kenfield, S. A., Wei, E. K., Stampfer, M. J., Rosner, B. A., & Colditz, G. A. (2008) · Tobacco Control · doi:10.1136/tc.2007.022582 · Cited by 289
Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends
Clegg, L. X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1537 · Cited by 278
US lung cancer trends by histologic type
Lewis, D. R., Check, D. P., Caporaso, N. E., Travis, W. D., & Devesa, S. S. (2014) · Cancer · doi:10.1002/cncr.28749 · Cited by 264
Feuer, E. J., Merrill, R. M., & Hankey, B. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.12.1025 · Cited by 251
Self-citationJatoi, I., Chen, B. E., Anderson, W. F., & Rosenberg, P. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2106 · Cited by 211
Jeon, J., Holford, T. R., Levy, D. T., Feuer, E. J., Cao, P., Tam, J., Clarke, L., Clarke, J., Kong, C. Y., & Meza, R. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1250 · Cited by 206
Self-citationDisparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States
Blom, E. F., ten Haaf, K., Arenberg, D. A., & de Koning, H. J. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201901-094oc · Cited by 123
Chu, K. C., Miller, B. A., Feuer, E. J., & Hankey, B. F. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90089-2 · Cited by 114
Self-citationLi, Y., Appius, A., Pattipaka, T., Feyereislova, A., Cassidy, A., & Ganti, A. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209709 · Cited by 64
Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends
Howlader, N., Morton, L. M., Feuer, E. J., Besson, C., & Engels, E. A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0921 · Cited by 57
Self-citationContributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States
Howlader, N., Shiels, M. S., Mariotto, A. B., & Engels, E. A. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0273 · Cited by 41
Self-citationUse of Multiple Imputation to Correct for Bias in Lung Cancer Incidence Trends by Histologic Subtype
Yu, M., Feuer, E. J., Cronin, K. A., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0130 · Cited by 23
Self-citation
Cited by
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Metadata
- Authors
- Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-13
- Volume
- 383
- Issue
- 7
- Pages
- 640-649
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3048896255
- Cited by
- 1,712
- References
- 34
- FWCI
- 75.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.